{"prompt": "['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'attenuated live vaccines.', '5.2.2 Permitted Concomitant Treatment', 'Any drugs other than those listed above are allowed, and should be administered, as necessary for', 'the treatment of the patient, when possible with a stable dose, at the discretion of the Investigator.', 'All treatment with these drugs should be recorded on the appropriate CRF.', '5.3 Storage, Accountability and Compliance', 'All study drugs must be kept in a secure place under adequate storage conditions - protected from', \"moisture and light. The patient will record the use of study medications in the Patient's Diary on a\", 'daily basis and the adherence to the prescribed treatment will be checked at every clinic visit. If there', 'are at least 14 days without study drugs intake (excluding a 14 days off the sunitinib in each cycle),', 'patient should be discontinued from the study.', '6. Study Measures', '6.1 Definitions of Efficacy Measures', '6.1.1 Objective Response Rate', 'Objective Response Rate (ORR) is defined as the percentage of patients who have achieved partial', 'response (PR) and complete response (CR) according to RECIST guidelines (version 1.1).', '6.1.2 Progression-free Survival', 'Progression-Free Survival (PFS) is defined as the time from the date of first dose investigational', 'products administration to the first date of objectively determined progressive disease (PD)', 'according to RECIST guidelines (version 1.1) or death from any cause. For patients not known to have', 'died as of the data cut-off date and who do not have objective PD, PFS will be censored at the date of', 'the last RECIST (version 1.1) assessment.', '6.1.3 Overall Survival', 'Overall Survival (OS) is defined as the time from the date of first dose investigational products', 'administration to the date of death from any cause. For patients not known to have died as of the', 'data cut-off date, os will be censored at the last contact date.', '6.1.4 Disease Control Rate', 'Disease Control Rate (DCR) is defined as the percentage of patients who have achieved partial', 'response (PR), complete response (CR) and stable disease (SD) according to RECIST guidelines', '(version 1.1).', '6.2 Safety Measures', 'Safety evaluation will rely on capturing all adverse events reported on vital signs, physical', 'examinations and laboratory tests. The CTCAE (version 4.0) will be used to standardize reported', 'adverse events of any kind.', 'Page 30 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', '6.3 Health-related Quality of Life Measures', 'The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire', '(EORTC QLQ-C30 version 3) and FACT-Kidney Symptom Index - 15 (FKSI-15) are validated and reliable', 'self-administered instruments that will be used to assess health-related quality of life.', '6.4 Disease-related Stress Measures', 'The 10-point Perceived Stress Scale (PSS) is validated and reliable self-administered instrument that', 'will be used to assess Disease-related Stress (DRS).', '6.5 Tumour Tissue and Serum Biomarkers Assessments', 'Formalin-fixed paraffin embedded primary tumour tissue (archival or recently biopsied) and serum', 'biomarkers will be used for exploratory analysis of potential pathway components or modulators', 'associated with RCC or the mechanism(s) of action of the study drugs.', '6.6 Timing and Methods of Measurements', '6.6.1 Pre-treatment Period', 'The protocol presents scheduled timelines for study procedures by abbreviated references to week', '(W) and day (D) (eg, W1D1, W3D1 etc) relative to the date of the first dose of study treatment', '(defined as W1D1).', 'Patients will be examined within 7 days prior to the first ingestion of the investigational products', 'during a screening visit to assess their eligibility to participate. Each subject will consent in writing to', 'the screening process before the start of the examination. The consent form will also include the', 'study information leaflet. The examinations and investigations will include:', 'medical history, including history of concomitant chronic diseases, allergies, use of medications,', 'demographics (date of birth, sex, race), alcohol and tobacco consumption patterns, family', 'history of cancer,', 'physical examination including assessment of general appearance, mouth, throat,', 'cardiovascular, lungs, abdomen and measurement of height and body weight. The examination', 'will be made in accordance with the normal clinical routines at the trial center,', 'vital signs: systolic and diastolic blood pressure, heart rate, pulse, respiratory rate, 02 saturation', 'and body temperature,', 'KPS score,', 'electrocardiography (ECG): standard 12-lead,', '24-hour Holter ECG monitoring,', 'echocardiography,', 'cardiology consultation,', 'Page 31 of 60']\n\n###\n\n", "completion": "END"}